Applications of Gene Therapy - Challenges in Delivery of Therapeutic Genomics and Proteomics - page 314

GL-67/DOPE/DMPE-PEG5000 formulation to the lungs of normal volunteers. Gene
Ther 1997;4:937-42.
[193] Chien KR. Molecular advances in cardiovascular biology. Science 1993;260:916-17.
[194] Staessen JA, Wang J, Bianchi G, Birkenhager WH. Essential hypertension. Lancet
2003;361:1629-41.
[195] Rader DJ, Cohen J, Hobbs HH. Monogenic hypercholesterolemia: new insights in
pathogenesis and treatment. J Clin Invest 2003;111:1795-803.
[196] Zhu X, Chang YP, Yan D, Weder A, Cooper R, Luke A, et al. Associations
between hypertension and genes in the renin-angiotensin system. Hypertension
2003;41:1027-34.
[197] Ambuhl P, Gyurko R, Phillips MI. A decrease in angiotensin receptor binding in rat
brain nuclei by antisense oligonucleotides to the angiotensin AT1 receptor. Regul Pept
1995;59:171-82.
[198] Gyurko R, Tran D, Phillips MI. Time course of inhibition of hypertension by antisense
oligonucleotides targeted to AT1 angiotensin receptor mRNA in spontaneously hyper-
tensive rats. Am J Hypertens 1997;10:56S-62S.
[199] Galli SM, Phillips MI. Angiotensin II AT (1A) receptor antisense lowers blood pressure
in acute 2-kidney, 1-clip hypertension. Hypertension 2001;38:674-8.
[200] Phillips MI, Mohuczy-Dominiak D, Coffey M, Galli GM, Kimura B, Wu P, et al.
Prolonged reduction of high blood pressure with an in vivo , nonpathogenic, adeno-asso-
ciated viral vector delivery of AT1-R mRNA antisense. Hypertension 1997;29:374-80.
[201] Wang H, Lu D, Reaves PY, Katovich MJ, Raizada MK. Retrovirally mediated deliv-
ery of angiotensin II type 1 receptor antisense in vitro and in vivo . Methods Enzymol
2000;314:581-90.
[202] Makino N, Sugano M, Ohtsuka S, Sawada S. Intravenous injection with antisense oli-
godeoxynucleotides against angiotensinogen decreases blood pressure in spontaneously
hypertensive rats. Hypertension 1998;31:1166-70.
[203] Chen H, Mohuczy D, Li D, Kimura B, Phillips MI, Mehta P, et al. Protection
against ischemia/reperfusion injury and myocardial dysfunction by antisense-
oligodeoxynucleotide directed at angiotensin-converting enzyme mRNA. Gene Ther
2001;8:804-10.
[204] Kubo T, Ikezawa A, Kambe T, Hagiwara Y, Fukumori R. Renin antisense injected intra-
ventricularly decreases blood pressure in spontaneously hypertensive rats. Brain Res
Bull 2001;56:23-8.
[205] Zhang YC, Bui JD, Shen L, Phillips MI. Antisense inhibition of beta (1)-adrenergic
receptor mRNA in a single dose produces a profound and prolonged reduction in high
blood pressure in spontaneously hypertensive rats. Circulation 2000;101:682-8.
[206] Channon KM, Guzik TJ. Mechanisms of superoxide production in human blood ves-
sels: relationship to endothelial dysfunction, clinical and genetic risk factors. J Physiol
Pharmacol 2002;53:515-24.
[207] Berry C, Hamilton CA, Brosnan MJ, Magill FG, Berg GA, McMurray JJV, et al.
Investigation into the sources of superoxide in human blood vessels: angiotensin II
increases superoxide production in human internal mammary arteries. Circulation
2000;101:2206-12.
[208] Nakane H, Miller FJ, Faraci FM, Toyoda K, Heistad DD. Gene transfer of endothe-
lial nitric oxide synthase reduces angiotensin II-induced endothelial dysfunction.
Hypertension 2000;35:595-601.
[209] Lin KF, Chao L, Chao J. Prolonged reduction of high blood pressure with human nitric
oxide synthase gene delivery. Hypertension 1997;30:307-13.